SCHEMBL736029

SCHEMBL736029

O=C([C@H](CCN1CCC2(CC2)[C@H](O)C1)N1CCN(c2ccc(Cl)c(Cl)c2)CCC1=O)N1CC(F)(F)C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAMTS5 Q9UNA0 7/20 0.38
HTR1A P08908 2/20 0.36
MMP2 P08253 4/20 0.36
RAB9A P51151 1/20 0.35
HTR2A P28223 1/20 0.35
HTR7 P34969 1/20 0.35
HTR6 P50406 1/20 0.35
NOTUM Q6P988 1/20 0.35
MAPT P10636 3/20 0.34
HTT P42858 2/20 0.34
MAPK1 P28482 1/20 0.34
DRD2 P14416 1/20 0.34
DRD4 P21917 1/20 0.34
DRD3 P35462 1/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34
RECQL P46063 1/20 0.34
KMT2A Q03164 1/20 0.34
ADAM17 P78536 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL736030 1.00 ADAMTS5 (0.38) ADAMTS5HTR1AMMP2RAB9AHTR2A
SCHEMBL13495283 0.91 ADAMTS5 (0.38) ADAMTS5HTR1AMMP2RAB9AHTR2A
SCHEMBL735214 0.91 HTR1A (0.40) ADAMTS5HTR1AMMP2RAB9AHTR2A
SCHEMBL735213 0.91 HTR1A (0.40) ADAMTS5HTR1AMMP2RAB9AHTR2A
SCHEMBL737154 0.89 HTR1A (0.40) ADAMTS5HTR1AMMP2RAB9AHTR2A
SCHEMBL737155 0.89 HTR1A (0.40) ADAMTS5HTR1AMMP2RAB9AHTR2A
SCHEMBL736806 0.88 HTR1A (0.39) ADAMTS5HTR1AMMP2RAB9AHTR2A
SCHEMBL736805 0.88 HTR1A (0.39) ADAMTS5HTR1AMMP2RAB9AHTR2A
SCHEMBL736078 0.87 HTR1A (0.37) ADAMTS5HTR1AMMP2RAB9AHTR2A
SCHEMBL736077 0.87 HTR1A (0.37) ADAMTS5HTR1AMMP2RAB9AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138175-B2 Heterocyclyl compounds HOFFMANN-LA ROCHE INC. (US) 2012-03-20 US disclosed
US-8138175-B2 Heterocyclyl compounds HOFFMANN-LA ROCHE INC. (US) 2012-03-20 US disclosed
US-8138175-B2 Heterocyclyl compounds HOFFMANN-LA ROCHE INC. (US) 2012-03-20 US disclosed
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-01-28 US disclosed
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-01-28 US disclosed
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS CCR2, CCR3, CCR5 ADAMTS5 4707/4885HTR1A 512/4885MMP2 3027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.